To further examine the therapeutic potential of targeting PLK4 to antagonize oxaliplatin resistance, we set up a tumor xenograft model in mice with oxaliplatin-responsive (vector) or -resistant (HCT116OR) HCT116 cells and monitored in vivo tumor growth upon oxaliplatin or CFI-400945 treatment. The gene discussed is PLK4; the disease is neoplasm.